Quick Takeaways
- VANGUARD GROUP INC filed SCHEDULE 13G for Lexeo Therapeutics Inc Common Stock (LXEO).
- Disclosed ownership: 5.3%.
- Date of event: 31 Dec 2025.
VANGUARD GROUP INC - 31 Dec 2025 SCHEDULE 13G Report for Lexeo Therapeutics Inc Common Stock (LXEO)
- Filing Manager
- VANGUARD GROUP INC
- Reporting Manager
- The Vanguard Group
- Security
- Lexeo Therapeutics Inc Common Stock
- Symbol
- LXEO
- Shares outstanding
- 73,063,977 shares
- Disclosed Ownership
- 3,894,310 shares
- Ownership
- 5.3%
- Form type
- SCHEDULE 13G
- Filing time
- 30 Jan 2026, 14:18:36 UTC
- Date of event
- 31 Dec 2025
- Next filing
- 27 Mar 2026
- SEC
- View on sec.gov
Quoteable Key Fact
"VANGUARD GROUP INC disclosed 5.3% ownership in Lexeo Therapeutics Inc Common Stock (LXEO) on 31 Dec 2025."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 30 Jan 2026, 14:18.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (1)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| The Vanguard Group | 5.3% | 3,894,310 | 0 | 421,792 | Ashley Grim | Head of Global Fund Administration |